[18F]PR04.MZ用于人脑多巴胺转运体PET/CT显像与定量的药代动力学评估
结果显示该示踪剂在纹状体和中脑摄取极高、非特异性结合极低,2TCM和SRTM均拟合良好,重测信度优良,静态显像60–90分钟可作为临床定量替代方案。
要点
- 2TCM为最优动力学模型,putamen、caudate、SNpc的Vt分别为11.83、9.73、2.12。
- SRTM非侵入性模型BPnd在putamen、caudate、SNpc分别为14.82、11.95、2.63。
- 纹状体和SNpc的BPnd在注射后90–130分钟稳定,静态显像60–90分钟可替代定量。
核心结论
- [18F]PR04.MZ对纹状体和中脑DAT具有高亲和力、高选择性及特异性摄取,2TCM和SRTM均能提供良好拟合和稳定的定量结果。
研究设计与样本
- 进行了血液和血浆代谢物分析、基于MRI的脑图像归一化、VOI勾画和动力学建模以确定Vt和BPnd。
- 评估了扫描时长的影响,并对5名受试者重复PET扫描以评估重测变异性。
主要发现
- [18F]PR04.MZ在循环中快速代谢,纹状体和中脑摄取极高,非特异性结合极低。
- 2TCM对时间-放射性曲线的拟合最佳,putamen、caudate、SNpc和小脑皮层的Vt分别为11.83、9.73、2.12和0.57。
- 所有非侵入性模型与2TCM衍生的BPnd相关性良好,但低估DAT可用性约28–33%。
- SRTM拟合最佳、AIC值最低,putamen、caudate和SNpc的BPnd分别为14.82、11.95和2.63。
- 重测结果显示所有区域变异性低,大多数相关区域可靠性优良。
关键数值与推荐
- 纹状体区域和SNpc的BPnd估计值在注射后90至130分钟之间保持稳定。
- 注射后60至90分钟的静态显像可作为定量的可行替代方案。
- SRTM提供了最佳拟合和最低的Akaike信息准则值。
临床怎么用
- 临床可采用注射后60–90分钟的静态显像方案进行DAT定量,无需动脉血采样。
- SRTM可作为非侵入性定量DAT的首选简化模型,但需注意其较2TCM低估BPnd约28–33%。
局限性
- 仅纳入健康受试者,未在神经系统疾病患者中验证。
- 非侵入性模型较2TCM低估DAT可用性约28–33%。
- 行动脉血采样的样本量仅5例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Dopamine transporters (DAT) modulate pre-synaptic dopamine and physiological functions such as movement and reward. DAT also mirrors disease state in neurological disorders, rendering it an essential diagnostic target. [18F]PR04.MZ is a new PET imaging agent for DAT with an improved affinity and selectivity profile, for which we here describe the complete pharmacokinetic evaluation in healthy controls. METHODS: Thirty-two healthy subjects underwent T1-weighted MRI and dynamic PET scans for 180 min with arterial blood sampling (n = 5) or 90 min without blood sampling (n = 25) after injection of 197.6 ± 12.2 MBq [18F]PR04.MZ. Blood and plasma metabolite analysis were performed. MRI-based normalization of brain images, delineation of VOIs, and kinetic modeling was conducted to determine distribution volumes (Vt) and binding potentials (BPnd). The impact of scan duration was evaluated and repeated PET scans were performed to assess test-retest variability (n = 5). A static imaging protocol has been validated for clinical applications. RESULTS: [18F]PR04.MZ showed rapid metabolization in circulation, very high uptake in striatum and midbrain, and very low non-specific binding. The two-tissue compartment model 2TCM provided best fits for measured time-activity-curves and calculated Vts in putamen, caudate, substantia nigra pars compacta (SNpc), and cerebellar cortex were 11.83, 9.73, 2.12, and 0.57, respectively. All non-invasive models correlated well with BPnd values derived from 2TCM but underestimated DAT availability by about 28-33%. Of those, simplified reference tissue model (SRTM) provided the best fits, lowest Akaike Information Criteria values, and BPnd values of 14.82, 11.95, and 2.63 in putamen, caudate, and SNpc, respectively. BPnd estimates for striatal regions and SNpc were stable between 90 and 130 min post-injection. Test-retest results were excellent, showing low variability in all and excellent reliability in most relevant regions. Static imaging from 60 to 90-min post-injection is a viable alternative for quantification. CONCLUSIONS: [18F]PR04.MZ is a PET tracer with very high affinity, selectivity, and specific uptake in striatum and midbrain. 2TCM and SRTM provide good fits, high and stable Vts or BPnds, and good test-retest reliability for precise quantification of DAT in human subjects.
引用
- Kramer V, Juri C, Riss PJ, et al. Pharmacokinetic evaluation of [18F]PR04.MZ for PET/CT imaging and quantification of dopamine transporters in the human brain. Eur J Nucl Med Mol Imaging. 2019. PMID: 31788709. doi:10.1007/s00259-019-04594-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。